Risks
3 risks
Risk Intelligence
Potential commission cap regulation
View Risks →Niva Bupa Health Insurance Co Ltd — Q4 FY26
Niva Bupa delivered a strong Q4 FY26 with GWP growth of 27.4% to ₹9,433 crore, driven by retail health growth of 35% and market share expansion to 10.4% in Q4.
bullish
high
Financial stats pending filing verification
2-Minute Summary
✦ AI-Generated from Full Transcript
Niva Bupa delivered a strong Q4 FY26 with GWP growth of 27.4% to ₹9,433 crore, driven by retail health growth of 35% and market share expansion to 10.4% in Q4. PAT surged 80% to ₹366 crore, with combined ratio improving 160 bps to 101.4% on operating leverage. Management guided for sustained retail industry growth of 17-19% CAGR and expects combined ratio to reach ~99% by FY29, with expense ratio savings offsetting modest loss ratio uptick. Key risks include potential commission cap regulation and competitive pressure from GST-driven volume growth normalization.
Risks3 trackedTranscriptfull text
Research workspace
Focused Modules
Transcript
Full text
Call Transcript
Full transcript text is available on this route.
Read Transcript →Quarter Snapshot
Retail Health Growth (H2 FY26)
40%+
+10pp vs industry
Retail health growth exceeded industry average of ~30% in H2 FY26, driven by GST tailwind.
Market Share (Retail Health, Q4 FY26)
10.4%
+1.4pp YoY
Market share in retail health increased from 9.0% in Q4 FY25 to 10.4% in Q4 FY26.
Expense of Management Ratio (FY26)
33.7%
-550bps YoY
EoM ratio improved from 39.2% in FY25 to 33.7% in FY26 due to operating leverage.
Solvency Ratio
2.49x
flat YoY
Solvency ratio remained healthy at 2.49x as of March 2026, well above regulatory minimum.
Fast read
Guidance and risk preview
Management expects combined ratio to improve to ~99% by FY29, driven by expense ratio savings of 200-250 bps.
Regulatory changes could cap commission rates, impacting distribution costs and growth.
View Risks →